Device Trial Radar · NCT06672588
Magnetic Seizure Therapy for Schizophrenia - Trial
Last checked: Nov 20, 2026Latest source record: Oct 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
80
Planned (sponsor's estimate)
Start
Apr 22, 2025
Primary completion
Nov 2028
Study completion Nov 2028
Sponsor
- Lead sponsor
- Centre for Addiction and Mental HealthAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- University of British Columbia
- First posted
- Nov 4, 2024
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This trial aims to assess the clinical effects and tolerability of Magnetic Seizure Therapy (MST) as an alternative to electroconvulsive therapy (ECT) for Treatment Resistant Schizophrenia (RS).
Conditions
- Treatment Resistant Schizophrenia
- Schizophrenia
- Schizoaffective Disorder
Interventions
Magnetic Seizure Therapy (MST)Device
MST treatment will be administered using the MagPro MST with a Cool TwinCoil over the frontal cortex in the midline position using 100 Hz stimulation at 100% machine output. Seizure threshold will follow prior protocols used for frontal MST. Patients will receive care and be managed by anaesthesia as per standard ECT practice.
Electroconvulsive Therapy (ECT)Device
In the ECT arm treatment, the MECTA sigma machine will be used. The ECT determination of seizure threshold and the adjustment of energy at subsequent sessions will be based on a standard published protocol. All participants will receive RUL-UB ECT at six times the seizure threshold. Patients will receive care and be managed by anaesthesia as per standard ECT practice.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Brief Psychiatric Rating Scale (BPRS) Response (18-Version)Time frame: Greater than 8 treatments (2.5 weeks)
- MATRICS™ Consensus Cognitive Battery (MCCB)Time frame: Greater than 8 treatments (2.5 weeks)
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
University of British Columbia Hospital
Vancouver, British Columbia, Canada · Recruiting
Centre for Addiction and Mental Health
Toronto, Ontario, Canada · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.